Key facts
- Delix Therapeutics’s last known valuation is $156.2M (Jun 2024).
- It has raised $108.5M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($70.0M) in Sep 2021.
- Notable investors include Gaingels, RA Capital Management, Calm Ventures, United States Department of War, Dolby Family Ventures — 40 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 40 names
- ·Watchlist + deal alerts for Delix Therapeutics
Funding rounds
1 roundsAbout Delix Therapeutics
Developer of neuroscience therapeutics designed to address mental health and central nervous system conditions. The company's platform discovers and develops non-hallucinogenic small molecules that induce selective neuroplasticity for therapeutic effects, enabling the treatment of depression, post-traumatic stress disorder, substance use disorders, and related neuropsychiatric and neurodegenerative diseases.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Bedford, MA, United States
- Founded
- 2019
- Employees
- 25
- Website
- delixtherapeutics.com/
- Ownership
- Privately Held (backing)
Delix Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Delix Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Delix Therapeutics in its N-PORT filings yet. We sweep new filings monthly.